Shots:Royalty Pharma & Biogen have entered into an agreement for the clinical development of litifilimab in SLE & CLE
As per the agreement, Biogen will receive ~$250M R&D funding over 6 quarters to support the development, whereas Royalty Pharma is entitled to receive regulatory milestones & mid-single digit royalties on global sales
…
